| $337M | ||
| $259M | ||
| $100M | ||
| $79M | ||
| $60M | ||
| $58M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.
Over the last 12 months, insiders at SAB Biotherapeutics, Inc. have bought $0 and sold $0 worth of SAB Biotherapeutics, Inc. stock.
On average, over the past 5 years, insiders at SAB Biotherapeutics, Inc. have bought $3.18M and sold $2,196 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,740 shares for transaction amount of $1,531 was made by Sullivan Eddie Joe (Chief Executive Officer) on 2023‑12‑07.
| 2023-12-07 | Sullivan Eddie Joe | Chief Executive Officer | 1,740 0.0034% | $0.88 | $1,531 | -63.29% | ||
| 2023-11-30 | King Michael | CHIEF FINANCIAL OFFICER | 5,000 0.0088% | $0.90 | $4,500 | -65.12% | ||
| 2023-11-29 | Reich Samuel J | Executive Chairman | 11,000 0.0209% | $0.89 | $9,842 | -61.03% | ||
| 2022-09-13 | HAMILTON CHRISTINE E | 10,000 0.0239% | $0.73 | $7,297 | +9.70% | |||
| 2022-09-07 | Sullivan Eddie Joe | CHIEF EXECUTIVE OFFICER | 14,000 0.0352% | $0.74 | $10,315 | +14.54% | ||
| 2021-10-26 | Sale | Beyer Russell P | Chief Financial Officer | 278 0.0005% | $7.90 | $2,196 | -79.14% | |
| 2021-10-14 | Reich Samuel J | CEO and CFO | 1,000 0.0023% | $10.11 | $10,110 | -77.38% | ||
| 2021-10-13 | Katz Ilan | 500 0.0012% | $10.11 | $5,053 | -77.23% | |||
| 2021-10-01 | Spragens Jeffrey G | director | 13,000 0.0299% | $10.07 | $130,910 | -74.98% | ||
| 2021-10-01 | Katz Ilan | 1,000 0.0023% | $10.09 | $10,090 | -74.98% | |||
| 2021-01-14 | Reich Samuel J | CEO and CFO | 417,200 0.9455% | $10.00 | $4.17M | +3300.68% | ||
| 2021-01-14 | Katz Ilan | 417,200 0.9455% | $10.00 | $4.17M | +3300.68% | |||
| 2021-01-14 | Big Cypress Holdings LLC | CEO and CFO | 417,200 0.9455% | $10.00 | $4.17M | +3300.68% |
| Sullivan Eddie Joe | Chief Executive Officer | 5232304 56.3116% | $13.45M | 2 | 0 | <0.0001% |
| HAMILTON CHRISTINE E | 4993090 53.7371% | $12.83M | 1 | 0 | +9.7% | |
| Big Cypress Holdings LLC | CEO and CFO | 3047825 32.8016% | $7.83M | 1 | 0 | |
| Reich Samuel J | Executive Chairman | 219001 2.357% | $562,832.57 | 3 | 0 | <0.0001% |
| Spragens Jeffrey G | director | 13000 0.1399% | $33,410.00 | 1 | 0 | <0.0001% |
| King Michael | CHIEF FINANCIAL OFFICER | 5000 0.0538% | $12,850.00 | 1 | 0 | <0.0001% |
| Katz Ilan | 1500 0.0161% | $3,855.00 | 3 | 0 | <0.0001% | |
| Beyer Russell P | Chief Financial Officer | 0 0% | $0 | 0 | 1 |
$155,580,641 | 77 | -24.21% | $23.91M | |
$17,268,389 | 57 | -18.16% | $25.73M | |
$6,204,522 | 45 | 1.91% | $27M | |
$395,438 | 43 | -21.25% | $22.47M | |
$1,443,732 | 36 | 10.14% | $21.07M | |
$1,995,470 | 22 | 14.01% | $22.81M | |
$139,007,129 | 16 | 47.16% | $27.24M | |
$25,487,383 | 15 | -4.37% | $21.6M | |
$156,484,110 | 12 | 52.55% | $27.07M | |
$19,300,035 | 11 | 45.88% | $31.78M | |
SAB Biotherapeutics, Inc. (SABS) | $189,648 | 9 | -52.20% | $23.88M |
$1,472,879 | 6 | -13.59% | $30.92M | |
$147,504 | 5 | -36.70% | $22.2M | |
$26,000,000 | 5 | -56.00% | $22.21M | |
$1,184,658 | 4 | -22.17% | $22.68M | |
$157,740 | 3 | 153.95% | $27.14M | |
$100,266 | 2 | 3.17% | $29.3M | |
$500,000 | 1 | -22.94% | $22.3M | |
$30,190 | 1 | -42.39% | $21.75M |
| Increased Positions | 9 | +29.03% | 61,111 | +2.3% |
| Decreased Positions | 11 | -35.48% | 525,034 | -19.79% |
| New Positions | 3 | New | 26,635 | New |
| Sold Out Positions | 4 | Sold Out | 509,606 | Sold Out |
| Total Postitions | 29 | -6.45% | 2M | -17.48% |
| Bvf Inc/Il | $1,469.00 | 10.2% | 917,826 | 0 | 0% | 2024-12-31 |
| Marshall Wace, Llp | $735.00 | 5.1% | 459,168 | 0 | 0% | 2024-12-31 |
| Sessa Capital Im, L.P. | $734.00 | 5.09% | 458,457 | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $444.00 | 3.08% | 277,375 | +1,039 | +0.38% | 2024-12-31 |
| Hb Wealth Management, Llc | $380.00 | 2.64% | 237,400 | +128,800 | +118.6% | 2024-12-31 |
| Geode Capital Management, Llc | $128.00 | 0.89% | 80,234 | +12,692 | +18.79% | 2024-12-31 |
| Pathstone Holdings, Llc | $81.00 | 0.56% | 50,650 | 0 | 0% | 2024-12-31 |
| Diadema Partners Lp | $48.00 | 0.33% | 30,000 | +30,000 | New | 2024-12-31 |
| Millennium Management Llc | $47.00 | 0.33% | 29,411 | -22,535 | -43.38% | 2024-12-31 |
| Blackrock, Inc. | $36.00 | 0.25% | 22,301 | -303 | -1.34% | 2025-03-31 |